593 related articles for article (PubMed ID: 35757739)
1. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.
Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
Front Immunol; 2022; 13():914577. PubMed ID: 35757739
[TBL] [Abstract][Full Text] [Related]
2. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance and Tumor Immune Microenvironment Heterogenicity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer.
Huang Z; Pan J; Wang H; Du X; Xu Y; Wang Z; Chen D
Front Cell Dev Biol; 2021; 9():657547. PubMed ID: 33928086
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of m5C regulatory genes in hepatocellular carcinoma.
Yang X; Yang F; Lan L; Wen N; Li H; Sun X
Front Genet; 2022; 13():972043. PubMed ID: 36105093
[No Abstract] [Full Text] [Related]
5. RNA m5C methylation orchestrates BLCA progression via macrophage reprogramming.
Yan D; Xie Y; Huang L; Zhang Y; Gu R; Xie H; Huang X; Luo H
J Cell Mol Med; 2023 Aug; 27(16):2398-2411. PubMed ID: 37408139
[TBL] [Abstract][Full Text] [Related]
6. ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment.
Pan W; Liu X; Liu S
Medicine (Baltimore); 2024 Apr; 103(14):e37590. PubMed ID: 38579085
[TBL] [Abstract][Full Text] [Related]
7. 5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma.
Liu T; Hu X; Lin C; Shi X; He Y; Zhang J; Cai K
Ann Transl Med; 2022 Mar; 10(5):259. PubMed ID: 35402591
[TBL] [Abstract][Full Text] [Related]
8. m5C regulator-mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine.
Chen B; Xi Y; Zhao J; Hong Y; Tian S; Zhai X; Chen Q; Ren X; Fan L; Xie X; Jiang C
Front Immunol; 2022; 13():1049435. PubMed ID: 36532062
[TBL] [Abstract][Full Text] [Related]
9. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.
Liu T; Sun L; Li ZZ; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Gastroenterol; 2023 May; 23(1):147. PubMed ID: 37170222
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a new molecular subtyping and prognostic signature with m6A/m5C/m1A/m7G regulatory genes for hepatocellular carcinoma.
Liu T; Wang Y; Li Z; Sun L; Yang K; Chen J; Han X; Qi L; Zhou X; Wang P
Heliyon; 2023 Nov; 9(11):e21285. PubMed ID: 38027812
[TBL] [Abstract][Full Text] [Related]
11. m5C regulator-mediated methylation modification phenotypes characterized by distinct tumor microenvironment immune heterogenicity in colorectal cancer.
Chen Z; Li Q; Lin Y; Lin S; Gao J; Chen S
Sci Rep; 2023 Jul; 13(1):11950. PubMed ID: 37488178
[TBL] [Abstract][Full Text] [Related]
12. The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma.
Li D; Li K; Zhang W; Yang KW; Mu DA; Jiang GJ; Shi RS; Ke D
Front Immunol; 2022; 13():918140. PubMed ID: 35833147
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
Zheng P; Li N; Zhan X
Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
[TBL] [Abstract][Full Text] [Related]
16. Development of the expression and prognostic significance of m
Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G
Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884
[TBL] [Abstract][Full Text] [Related]
17. An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer.
Yun D; Yang Z; Zhang S; Yang H; Liu D; Grützmann R; Pilarsky C; Britzen-Laurent N
Front Cell Dev Biol; 2022; 10():975684. PubMed ID: 36060802
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
19. Identification of M5c regulator-medicated methylation modification patterns for prognosis and immune microenvironment in glioma.
Xiao Z; Li J; Liang C; Liu Y; Zhang Y; Zhang Y; Liu Q; Yan X
Aging (Albany NY); 2023 Nov; 15(21):12275-12295. PubMed ID: 37934565
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
